These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38112526)

  • 21. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Chirehwa M; Winckler JL; Mao J; Draper HR; Wiesner L; Norman J; McIlleron H; Donald PR; Hesseling AC; Denti P
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226421. PubMed ID: 35506699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China.
    Wu HY; Tian Y; Wang XD; Sun JS; Fan LC; Chen MX; Li R; Chen Y
    J Paediatr Child Health; 2022 Jan; 58(1):116-121. PubMed ID: 34323328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies.
    Garcia-Prats AJ; Schaaf HS; Draper HR; Garcia-Cremades M; Winckler J; Wiesner L; Hesseling AC; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002789. PubMed ID: 31039153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
    Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis.
    Olliaro PL; Merle C; Mthiyane T; Bah B; Kassa F; Amukoye E; N Diaye A; Perronne C; Lienhardt C; McIlleron H; Fielding K
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clofazimine pharmacokinetics in patients with TB: dosing implications.
    Abdelwahab MT; Wasserman S; Brust JCM; Gandhi NR; Meintjes G; Everitt D; Diacon A; Dawson R; Wiesner L; Svensson EM; Maartens G; Denti P
    J Antimicrob Chemother; 2020 Nov; 75(11):3269-3277. PubMed ID: 32747933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
    Heysell SK; Mpagama SG; Ogarkov OB; Conaway M; Ahmed S; Zhdanova S; Pholwat S; Alshaer MH; Chongolo AM; Mujaga B; Sariko M; Saba S; Rahman SMM; Uddin MKM; Suzdalnitsky A; Moiseeva E; Zorkaltseva E; Koshcheyev M; Vitko S; Mmbaga BT; Kibiki GS; Pasipanodya JG; Peloquin CA; Banu S; Houpt ER
    Clin Infect Dis; 2023 Feb; 76(3):497-505. PubMed ID: 35731948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
    Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
    Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T-wave morphology abnormalities in the STREAM stage 1 trial.
    Hughes G; Young WJ; Bern H; Crook A; Lambiase PD; Goodall RL; Nunn AJ; Meredith SK
    Expert Opin Drug Saf; 2024 Apr; 23(4):469-476. PubMed ID: 38462751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
    Galileya LT; Wasmann RE; Chabala C; Rabie H; Lee J; Njahira Mukui I; Hesseling A; Zar H; Aarnoutse R; Turkova A; Gibb D; Cotton MF; McIlleron H; Denti P
    PLoS Med; 2023 Nov; 20(11):e1004303. PubMed ID: 37988391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
    Elsherbiny D; Ren Y; McIlleron H; Maartens G; Simonsson US
    Eur J Clin Pharmacol; 2010 Oct; 66(10):1017-23. PubMed ID: 20552180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB.
    Nie Q; Tao L; Li Y; Chen N; Chen H; Zhou Y; Wang Y; Chen H; Tang Q; Wang X; Huang C; Yang C
    Int J Infect Dis; 2022 Feb; 115():142-148. PubMed ID: 34861398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and Optimal Dosing of Levofloxacin in Children for Drug-Resistant Tuberculosis: An Individual Patient Data Meta-Analysis.
    White YN; Solans BP; Denti P; van der Laan LE; Schaaf HS; Vonasek B; Malik AA; Draper HR; Hussain H; Hesseling AC; Garcia-Prats AJ; Savic RM
    Clin Infect Dis; 2024 Mar; 78(3):756-764. PubMed ID: 38340060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study.
    Isralls S; Baisley K; Ngam E; Grant AD; Millard J
    Open Forum Infect Dis; 2021 Aug; 8(8):ofab413. PubMed ID: 34466629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.
    van der Laan LE; Garcia-Prats AJ; Schaaf HS; Tikiso T; Wiesner L; de Kock M; Winckler J; Norman J; McIlleron H; Denti P; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data.
    Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N
    Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of mortality and treatment success of multi-drug resistant and Rifampicin resistant tuberculosis in Zimbabwe: a retrospective cohort analysis of patients initiated on treatment during 2010 to 2015.
    Matambo R; Nyandoro G; Sandy C; Nkomo T; Mutero-Munyati S; Mharakurwa S; Chikaka E; Ngwenya M; Ndongwe G; Pepukai VM
    Pan Afr Med J; 2021; 39():128. PubMed ID: 34527144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.